Bank of New York Mellon Corp Makes New Investment in Integra LifeSciences Holdings Corporation $IART

Key Points

• Bank of New York Mellon purchased 485,672 Integra LifeSciences shares worth approximately $8.7 million, while other institutions also increased their holdings. Institutional investors and hedge funds now own 84.78% of IART.
• Integra reported quarterly EPS of $0.56, beating the $0.48 consensus estimate, on revenue of $418.76 million. Management guided for third-quarter EPS of $0.53–$0.61 and full-year 2026 EPS of $2.40–$2.50.
• IART shares opened at $16.81, up 1.1%, but analysts remain cautious: the stock has a consensus “Reduce” rating and an average price target of $18.86.

Bank of New York Mellon Corp purchased a new position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 485,672 shares of the life sciences company's stock, valued at approximately $8,723,000. Bank of New York Mellon Corp owned approximately 0.62% of Integra LifeSciences at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. Glenmede Trust Co. NA increased its stake in shares of Integra LifeSciences by 27.4% during the 1st quarter. Glenmede Trust Co. NA now owns 984,686 shares of the life sciences company's stock worth $9,276,000 after purchasing an additional 211,774 shares during the last quarter. Access Investment Management LLC boosted its holdings in Integra LifeSciences by 72.0% in the first quarter. Access Investment Management LLC now owns 640,535 shares of the life sciences company's stock worth $6,034,000 after purchasing an additional 268,085 shares in the last quarter. Bank of America Corp DE boosted its holdings in Integra LifeSciences by 71.4% in the first quarter. Bank of America Corp DE now owns 1,414,509 shares of the life sciences company's stock worth $13,325,000 after purchasing an additional 589,408 shares in the last quarter. Amundi increased its position in Integra LifeSciences by 80.8% during the first quarter. Amundi now owns 19,430 shares of the life sciences company's stock worth $183,000 after buying an additional 8,681 shares during the last quarter. Finally, Maverick Capital Ltd. acquired a new position in Integra LifeSciences during the first quarter worth $679,000. 84.78% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Stock Up 1.1%

Shares of IART stock opened at $16.81 on Thursday. Integra LifeSciences Holdings Corporation has a 12 month low of $8.70 and a 12 month high of $20.49. The company has a quick ratio of 2.11, a current ratio of 3.60 and a debt-to-equity ratio of 1.75. The firm has a market cap of $1.31 billion, a PE ratio of -186.76, a price-to-earnings-growth ratio of 0.85 and a beta of 1.21. The stock has a 50 day moving average of $17.87 and a 200-day moving average of $14.40.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The life sciences company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.08. Integra LifeSciences had a negative net margin of 0.44% and a positive return on equity of 18.30%. The business had revenue of $418.76 million for the quarter, compared to the consensus estimate of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. On average, equities analysts predict that Integra LifeSciences Holdings Corporation will post 2.46 EPS for the current year.

Analyst Upgrades and Downgrades

IART has been the subject of a number of analyst reports. UBS Group initiated coverage on Integra LifeSciences in a research report on Tuesday, July 28th. They issued a "neutral" rating and a $19.00 price target for the company. Argus raised Integra LifeSciences from a "hold" rating to a "buy" rating and set a $25.00 price objective on the stock in a report on Thursday, June 18th. Wall Street Zen downgraded Integra LifeSciences from a "strong-buy" rating to a "buy" rating in a research note on Saturday, July 18th. BMO Capital Markets initiated coverage on Integra LifeSciences in a report on Wednesday, July 8th. They issued a "market perform" rating and a $19.00 target price for the company. Finally, Citigroup reaffirmed a "neutral" rating and set a $19.00 target price (up from $16.00) on shares of Integra LifeSciences in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Buy rating, five have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Integra LifeSciences currently has a consensus rating of "Reduce" and an average target price of $18.86.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.

Want to see what other hedge funds are holding IART? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Integra LifeSciences Holdings Corporation (NASDAQ:IART - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source